MetLife Investment Advisors LLC lifted its stake in Mirati Therapeutics Inc (NASDAQ:MRTX) by 11.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,577 shares of the biotechnology company’s stock after buying an additional 983 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Mirati Therapeutics were worth $702,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in shares of Mirati Therapeutics by 88.6% in the 1st quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock worth $149,147,000 after purchasing an additional 956,022 shares during the period. BlackRock Inc. lifted its stake in shares of Mirati Therapeutics by 30.0% during the 4th quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock worth $87,086,000 after acquiring an additional 474,097 shares during the last quarter. TimesSquare Capital Management LLC bought a new stake in shares of Mirati Therapeutics during the 1st quarter worth approximately $17,687,000. Perceptive Advisors LLC bought a new stake in shares of Mirati Therapeutics during the 4th quarter worth approximately $5,250,000. Finally, Amundi Pioneer Asset Management Inc. raised its position in Mirati Therapeutics by 44.8% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 268,100 shares of the biotechnology company’s stock valued at $11,373,000 after purchasing an additional 82,900 shares in the last quarter.
Mirati Therapeutics stock traded up $2.59 during mid-day trading on Thursday, hitting $105.89. The company’s stock had a trading volume of 298,402 shares, compared to its average volume of 710,362. The firm has a market cap of $3.73 billion, a price-to-earnings ratio of -33.19 and a beta of 2.02. Mirati Therapeutics Inc has a 1 year low of $28.50 and a 1 year high of $109.64. The business has a fifty day moving average price of $98.68.
In other Mirati Therapeutics news, Director Michael G. Grey sold 5,760 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $65.30, for a total transaction of $376,128.00. Following the transaction, the director now owns 7,100 shares of the company’s stock, valued at $463,630. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce L. A. Carter sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $75.20, for a total value of $225,600.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $225,600. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,260 shares of company stock worth $1,164,228. 4.86% of the stock is owned by insiders.
A number of equities research analysts have weighed in on MRTX shares. HC Wainwright reaffirmed a “buy” rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th. JPMorgan Chase & Co. restated a “buy” rating and set a $69.00 target price on shares of Daimler in a research note on Friday, July 12th. Barclays reiterated an “overweight” rating and set a GBX 3,150 ($41.16) price target on shares of in a research note on Wednesday, June 5th. B. Riley set a $14.00 price target on SM Energy and gave the company a “hold” rating in a research note on Wednesday, June 19th. Finally, Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. Mirati Therapeutics presently has an average rating of “Buy” and a consensus target price of $94.70.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
Further Reading: Trade Deficit
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.